Skip to main content
Zhaoying Zhang on Muck Rack

Zhaoying Zhang

As seen in: Wiley Online Library, Science Magazine, BioRxiv, Dialnet - Universidad de La Rioja
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhaoying

Contact Zhaoying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Improving GPP and SIF Simulation With a Mechanistic Photosynthesis Model Integrated Into the BEPS Framework

|
By Yue Liu, Zhaoying Zhang, Jennifer Johnson
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The tower-based GPP and SIF data used in this study are publicly available at https://climatesciences.jpl.nasa.gov/sif/download-data/tower/. MODIS LAI products are publicly available at http://doi.org/10.5067/MODIS/MYD15A2H.006. The BEPS-SIF model code can be accessed on GitHub at https://github.com/yongguangzhang/BEPS-SIF-model.git.
Open in Who Shared Issue with article?

Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis Click to copy article link Article link copied!

|
By Xin Qin, Zhaoying Zhang, Tong Wei
| dx.doi.org
Open in Who Shared Issue with article?

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma

|
By Olivier Demaria, Zhaoying Zhang, Yexin Yang, Guillaume Habif
| Science Magazine Verified
Editor’s summary Current treatments for B cell–specific non-Hodgkin lymphoma (B-NHL) target CD20+ cancerous B cells but have limited efficacy in relapsed or refractory patients. Demaria et al. developed an antibody-based molecule that targets B-NHL by engaging natural killer (NK) cells with antitumor activity.
Open in Who Shared Issue with article?
See all 28 articles